Chromatography approaches for early screening of the phospholipidosis-inducing potential of pharmaceuticals

Journal of Pharmaceutical and Biomedical Analysis

Volumn 61, Issue , 2012, Pages 184-190

  Jiang, Zhengjin ^a   Reilly, John ^b  

^a JINAN UNIVERSITY   (China)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

Drug phospholipidosis inducing potential; Phospholipidosis; Surfactant vesicle electrokinetic chromatography; Volume of distribution

Indexed keywords

AMIODARONE; AMITRIPTYLINE; AMPICILLIN; ATENOLOL; ATROPINE; CHLOROQUINE; CLOMIPRAMINE; DIAZEPAM; DISOPYRAMIDE; DOCUSATE SODIUM; FAMOTIDINE; FLUOXETINE; FUROSEMIDE; IMIPRAMINE; KETOPROFEN; LABETALOL; LIDOCAINE; MAPROTILINE; MEPACRINE; MIANSERIN; OCTANOL; PARACETAMOL; PROCAINE; PROPRANOLOL; QUINIDINE; TAMOXIFEN; TETRACYCLINE; UNINDEXED DRUG; WARFARIN; ZIMELDINE;

ARTICLE; DISTRIBUTION VOLUME; DRUG DETERMINATION; HIGH THROUGHPUT SCREENING; HUMAN; LIPID STORAGE; LIPIDOSIS; MICELLAR ELECTROKINETIC CHROMATOGRAPHY; PHYSICAL CHEMISTRY; PRIORITY JOURNAL;

CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY; HUMANS; LIPIDOSES; PHARMACEUTICAL PREPARATIONS; PHOSPHOLIPIDS;

EID: 84856101453     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2011.11.033     Document Type: Article

References (44)

1. Anderson N., Borlak J. Drug-induced phospholipidosis. FEBS Lett. 2006, 580:5533-5540.
2. Reasor M.J., Kacew S. Drug-induced phospholipidosis: are there functional consequences?. Exp. Biol. Med. 2001, 226:825-830.
3. Kodavanti U.P., Mehendale H.M. Cationic amphiphilic drugs and phospholipid storage disorder. Pharmacol. Rev. 1990, 42:327-354.
4. Halliwell W.H. Cationic amphiphilic drug-induced phospholipidosis. Toxicol. Pathol. 1997, 25:53-60.
5. Reasor M.J. A review of the biology and toxicologic implications of the induction of lysosomal lamellar bodies by drugs. Toxicol. Appl. Pharmacol. 1989, 97:47-56.
6. Reasor M.J., Ogle C.L., Kacew S. Amiodarone-induced pulmonary toxicity in rats: biochemical and pharmacological characteristics. Toxicol. Appl. Pharmacol. 1989, 97:124-133.
7. Berridge B.R., Chatman L.A., Odin M., Schultze A.E., Losco P.E., Meehan J.T., Peters T., Vonderfecht S.L. Phospholipidosis in nonclinical toxicity studies. Toxicol. Pathol. 2007, 35:325.
8. Cerep, Phospholipidosis, ADME-Tox Application note 2009.
9. Alakoskela J.-M., Vitovič P., Kinnunen P.J. Screening for the drug-phospholipidosis interaction: correlation to phospholipidosis. ChemMedChem 2009, 4:1224-1251.
10. Van Bambeke F., Gerbaux C., Michot J.M., d'Yvoire M.B., Montenez J.P., Tulkens P.M. Lysosomal alterations induced in cultured rat fibroblasts by long-term exposure to low concentrations of azithromycin. J. Antimicrob. Chemother. 1998, 42:761-767.
11. Hostetler K.Y., Vandeberg J., Aldern K.A., Brophy G.T. Effect of amiodarone on the phospholipid and lamellar body content of lymphoblasts in vitro and peripheral blood lymphocytes in vivo. Biochem. Pharmacol. 1991, 41:1007-1013.
12. Gum R.J., Hickman D., Fagerland J.A., Heindel M.A., Gagne G.D., Schmidt J.M., Michaelides M.R., Davidsen S.K., Ulrich R.G. Analysis of two matrix metalloproteinase inhibitors and their metabolites for induction of phospholipidosis in rat and human hepatocytes. Biochem. Pharmacol. 2001, 62:1661-1673.
13. Ulrich R.G., Kilgore K.S., Sun E.L., Cramer C.T., Ginsberg L.C. An in vitro fluorescence assay for the detection of drug-induced cytoplasmic lamellar bodies. Toxicol. Methods 1991, 1:89-105.
14. Kasahara T., Tomita K., Murano H., Harada T., Tsubakimoto K., Ogihara T., Ohnishi S., Kakinuma C. Establishment of an in vitro high-throughput screening assay for detecting phospholipidosis-inducing potential. Toxicol. Sci. 2006, 90:133-141.
15. Morelli J.K., Buehrle M., Pognan F., Barone L.R., Fieles W., Ciaccio P.J. Validation of an in vitro screen for phospholipidosis using a high content biology platform. Cell Biol. Toxicol. 2006, 22:15-27.
16. Sawada H., Takami K., Asahi S. A toxicogenomic approach to drug-induced phospholipidosis: analysis of its induction mechanism and establishment of a novel in vitro screening system. Toxicol. Sci. 2005, 83:282-292.
17. Vitovic P., Alakoskela J.M., Kinnunen P.K.J. Assessment of drug-lipid complex formation by a high-throughput langmuir-balance and correlation to phospholipidosis. J. Med. Chem. 2008, 51:1842-1848.
18. Reasor M.J., Hastings K.L., Ulrich R.G. Drug-induced phospholipidosis: issues and future directions. Expert Opin. Drug Saf. 2006, 5:567-583.
19. 14C] amiodarone uptake by perfused lung. Am. J. Respir. Cell Mol. Biol. 1991, 4:369-378.
20. Ploemen J.P.H.T.M., Kelder J., Hafmans T., van de Sandt H., van Burgsteden J.A., Salemink P.J.M., Van Esch E. Exp Use of physicochemical calculation of pKa and ClogP to predict phospholipidosis-inducing potential. Toxicol. Pathol. 2004, 55:347-355.
21. Tomizawa K., Sugano K., Yamada H., Horii I. Physicochemical and cell-based approach for early screening of phospholipidosis-induced potential. J. Toxicol. Sci. 2006, 31:315-324.
22. Zhou L., Geraci G., Hess S., Yang L., Wang J., Argika U. Predicting phospholipidosis: a fluorescence noncell based in vitro assay for the determination of drug-phospholipid complex formation in early drug discovery. Anal. Chem. 2011, 83:6980-6987.
23. Adejare A., El-Gendy A. Prediction of intestinal and blood brain barrier permeability utilizing immobilized artifical membrane chromatography. Abstracts of Papers of the American Chemical Society, vol. 228 2004, p. U960.
24. Liu H.L., Ong S.W., Glunz L., Pidgeon C. Predicting drug-membrane interactions by HPLC: structural requirements of chromatographic surfaces. Anal. Chem. 1995, 67:3550-3557.
25. Pidgeon C., S.W.Ong, Liu H.L., Qiu X.X., Pidgeon M., Dantzig A.H., Munroe J., Hornback W.J., Kasher J.S., Glunz L., Szczerba T. IAM chromatography: an in vitro screen for predicting drug membrane permeability. J. Med. Chem. 1995, 38:590-594.
26. Reichel A., Begley D.J. Potential of immobilized artificial membranes for predicting drug penetration across the blood-brain barrier. Pharm. Res. 1998, 15:1270-1274.
27. Taillardat-Bertschinger A., Martinet C.A.M., Carrupt P.A., Reist M., Caron G., Fruttero R., Testa B. Molecular factors influencing retention on immobilized artificial membranes (IAM) compared to partitioning in liposomes and n-octanol. Pharm. Res. 2002, 19:729-737.
28. Carrozzino J.M., Khaledi M.G. Interaction of basic drugs with lipid bilayers using liposome electrokinetic chromatography. Pharm. Res. 2004, 21:2327-2335.
29. Carrozzino J.M., Khaledi M.G. pH Effects on drug interactions with lipid bilayers by liposome electrokinetic chromatography. J. Chromatogr. A 2005, 1079:307-316.
30. Jiang Z., Reilly J., Everatt B. A method for rapidly predicting drug tissue distribution using surfactant vesicle electrokinetic chromatography. Electrophoresis 2008, 29:3674-3684.
31. Pascoe R.J., Masucci J.A., Foley J.P. Investigation of vesicle electrokinetic chromatography as an in vitro assay for the estimation of intestinal permeability of pharmaceutical drug candidates. Electrophoresis 2006, 27:793-804.
32. Casartelli A., Bonato M., Cristofori P., Crivellente F., Dal Negro G., Masotto I., Mutinelli C., Valko K., Bonfante V. A cell-based approach for the early assessment of the phospholipidogenic potential in pharmaceutical research and drug development. Cell Biol. Toxicol. 2003, 19:161-176.
33. Valko K., Du C.M., Bevan C.D., Reynolds D.P., Abraham M.H. Rapid-gradient HPLC method for measuring drug interactions with immobilized artificial membrane: comparison with other lipophilicity measures. J. Pharm. Sci. 2000, 89:1085-1096.
34. Valko K., Nunhuck S., Bevan C., Abraham M.H., Reyncilds D.P. Fast gradient HPLC method to determine compounds binding to human serum albumin. Relationships with octanol/water and immobilized artificial membrane lipophilicity. J. Pharm. Sci. 2003, 92:2236-2248.
35. Kerns E.H., Di L., Petusky S., Kleintop T., Huryn D., McConnell O., Carter G. Pharmaceutical profiling method for lipophilicity and integrity using LC/MS. J. Chromatogr. B 2003, 791:381-388.
36. Hollosy F., Valko K., Hersey A., Nunhuck S., Keri G., Bevan C. Estimation of volume of distribution in humans from high throughput HPLC-based measurements of human serum albumin binding and immobilized artificial membrane partitioning. J. Med. Chem. 2006, 49:6958-6971.
37. Reasor M.J., McCloud C.M., DiMatteo M., Schafer R., Ima A., Lemaire I. Effects of amiodarone-induced phospholipidosis on pulmonary host defense functions in rats. Proc. Soc. Exp. Biol. Med. 1996, 211:346-352.
38. Reasor M.J., Kacew S. Amiodarone pulmonary toxicity: morphologic and biochemical features. Proc. Soc. Exp. Biol. Med. 1991, 196:1-7.
39. Jägel M., Lüllmann-Rauch R. Lipidosis-like alterations in cultured macrophages exposed to local anaesthetics. Arch. Toxicol. 1984, 55:229-232.
40. Lüllmann-Rauch R., Reil G.H. Fenfluramine-induced ultrastructural alterations in tissues of rats and guinea pigs. Naunyn Schmiedeberg's Arch. Pharmacol. 1974, 285:175-184.
41. Xia Z.L., Ying G., Hansson A.L., Karlsson H., Xie Y., Bergstrand A., DePierre J.W., Nässberger L. Antidepressant-induced lipidosis with special reference to tricyclic compounds. Prog. Neurobiol. 2000, 60:501-512.
42. Nioi P., Perry B.K., Wang E.J., Gu Y.Z., Snyder R.D. In vitro detection of drug-induced phospholipidosis using gene expression and fluorescent phospholipid-based methodologies. Toxicol. Sci. 2007, 99:162-173.
43. Pappu A.S., Yazaki P.J., Hostetler K.Y. Inhibition of purified lysosomal phospholipase A1 by various beta andrenergic blockers. Biochem. Pharmacol. 1985, 34:521-524.
44. Monteith D.K., Morgan R.E., Halstead B. In vitro assays and biomarkers for drug-induced phospholipidosis. Expert Opin. Drug Metab. Toxicol. 2006, 2:687-696.